Skip to contents

Scott J. Rodig, MD, PhD
Associate Pathologist, Brigham and Women's Hospital
Associate Professor of Pathology, Harvard Medical School

Brigham and Women's Hospital
Department of Pathology
75 Francis Street
Boston, MA 02115

Research Location: Thorn Research Building


Edit Profile


Research Narrative:

Dr. Rodig is an anatomic and molecular pathologist at Brigham & Womens Hospital, Director of the Hematopathology Fellowship at Brigham & Women's Hospital, Director of the Tissue Biomarker Laboratory of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute, and an Associate Professor of Pathology at Harvard Medical School.  Dr. Rodigs laboratory focuses on the development and application of novel tissue-based biomarker assays to improve the diagnosis of and to guide therapy for human cancer.  Techniques his group employ include targeted genetic testing with customized fluorescence in-situ hybridization (FISH) probes, targeted gene expression profiling, and multiplex immunofluorescence staining coupled with digital image analysis.  His group has discovered and characterized disease mechanisms underlying Hodgkin lymphoma, diffuse large B-cell lymphoma, specialized forms of lung cancer, and melanoma that have resulted in new diagnostic tests to direct clinical trial enrollment and personalized therapy.

 

 


Education:
Washington University in St. Louis, 1998, MD
Washington University in St. Louis, 1998, PhD

Publications (Pulled from Harvard Catalyst Profiles):

1. Rodig SJ. Detecting Gold-Labeled Cells. Cold Spring Harb Protoc. 2019 Jul 01; 2019(7):pdb.prot099754.

2. Rodig SJ. Detecting Iodine-Labeled Cells. Cold Spring Harb Protoc. 2019 Jul 01; 2019(7):pdb.prot099762.

3. Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su MJ, Felt K, Gjini E, Brais LK, Rotem A, Rosenthal MH, Rozenblatt-Rosen O, Rodig S, Ng K, Van Allen EM, Corsello SM, Ogino S, Regev A, Nowak JA, Giannakis M. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 Aug; 7(8):1230-1236.

4. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019 Jun 19; 11(497).

5. Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019 Jun 10; 35(6):885-900.e10.

6. Ramchandren R, Domingo-Domènech E, Rueda A, Trnený M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019 Aug 10; 37(23):1997-2007.

7. Nabel CS, Severgnini M, Hung YP, Cunningham-Bussel A, Gjini E, Kleinsteuber K, Seymour LJ, Holland MK, Cunningham R, Felt KD, Vivero M, Rodig SJ, Massarotti EM, Rahma OE, Harshman LC. Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. Oncologist. 2019 May 14.

8. Gjini E, Jing CB, Nguyen AT, Reyon D, Gans E, Kesarsing M, Peterson J, Pozdnyakova O, Rodig SJ, Mansour MR, Joung K, Look AT. Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. Dis Model Mech. 2019 05 07; 12(5).

9. Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res. 2019 Aug 01; 25(15):4644-4655.

10. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 Jul 04; 134(1):22-29.